Dana-Farber Cancer Institute | Strategic Alliance Partners

Researchers used a genome-wide CRISPR knockout screen to pinpoint genes that help human AML cells avoid being engulfed by macrophages.

Multicancer early detection testing has emerged as an exciting strategy to expand cancer screening.

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Jennifer R. Brown, MD, PhD, discusses ongoing clinical trials that she has her eye out for in chronic lymphocytic leukemia.

Kathleen Burns, MD, PhD, of has been elected as Fellow of the American Association for the Advancement of Science.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinb and venetoclax for chronic lymphocytic leukemia and its effect on patient QOL.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Xiao Wei, MD, MAS, discusses the FDA approval of Pylarify TruVu for detecting PSMA-positive lesions in prostate cancer.

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Drs Rotow and Dietrich discuss the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated NSCLC.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

A detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas.

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

Sarah Sammons, MD, discusses efficacy data from a phase 2 study of pumitamig in patients with locally advanced or metastatic triple-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Dr Sammons discusses the rationale for and findings from a phase 2 study evaluating pumitamig in patients with locally advanced or metastatic TNBC.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.